Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
299.81(c) 301.94(c) 295.95(c) 299.21(c) 300 Last
1 380 418 797 533 1 039 040 1 125 808 253 433 Volume
-0.11% +0.71% -1.98% +1.10% +0.26% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 10 783 M - -
Net income 2021 1 967 M - -
Net Debt 2021 1 558 M - -
P/E ratio 2021 22,8x
Yield 2021 -
Sales 2022 11 311 M - -
Net income 2022 2 744 M - -
Net cash position 2022 1 480 M - -
P/E ratio 2022 17,0x
Yield 2022 -
Capitalization 44 592 M 44 592 M -
EV / Sales 2021 4,28x
EV / Sales 2022 3,81x
Nbr of Employees 9 100
Free-Float 84,9%
More Financials
Company
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment... 
Sector
Pharmaceuticals
Calendar
09/21 | 10:00am
More about the company
Ratings of Biogen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIOGEN INC.
10:26aBIOGEN : Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a High..
AQ
09:57aBIOGEN : UBS Adjusts Biogen PT to $442 From $475, Maintains Buy Rating
MT
08:20aBIOGEN : Study of Vixotrigine in Small Fiber Neuropathy Meets One Endpoint, Miss..
MT
07:30aBIOGEN : Announces Positive Topline Results from Phase 2 CONVEY Study in Small F..
AQ
06:05aBiogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 2..
DJ
09/15BIOGEN : Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021
PU
09/15Correction to Biogen Plans Phase 3b Trial Article
DJ
09/15BIOGEN : to Conduct Phase 3b Study of Higher Dose of Nusinersen in Patients Prev..
MT
09/15BIOGEN : Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a High..
AQ
09/15Biogen Inc Announces Plans to Initiate Global Phase 3B Clinical Study, ASCEND
CI
09/15Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
DJ
09/10S&P 500 Limps Into Close as Late Sell-Off Caps Worst Week Since February
MT
09/10VIDEO : This week's gainers and losers
09/10Japan's Topix hits highest since 1990 on hopes of new govt, better earnings
RE
09/09Japan shares rally on, Topix hits over 30-year high on earnings optimism
RE
More news
News in other languages on BIOGEN INC.
08:20aL'étude de Biogen sur la vixotrigine dans la neuropathie à petites fibres att..
09/10L'indice S&P 500 se rapproche de la fin de la semaine, alors que le repli tar..
09/10PUMP / DUMP #28 : Les Tops & Flops de la semaine
09/10Wall Street : s'essouffle au final, mais repli sans intensité
09/09Wall Street : s'essouffle au final, mais repli sans intensité
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Last Close Price 299,21 $
Average target price 423,24 $
Spread / Average Target 41,5%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors